Analysis, secure access to, and transmission of array images
View Patent ↗Systems and methods are provided the autocentering, autofocusing, acquiring, decoding, aligning, analyzing and exchanging among various parties, images, where the images are of arrays of signals associated with ligand-receptor interactions, and more particularly, ligand-receptor interactions where a multitude of receptors are associated with microparticles or microbeads. The beads are encoded to indicate the identity of the receptor attached, and therefore, an assay image and decoding image are aligned to effect the decoding. The images or data extracted from such images can be exchanged between de-centralized assay locations and a centralized location where the data are analyzed to indicate assay results. Access to data can be restricted to authorized parties in possession of certain encoding information, so as to preserve confidentiality.
1. A method of conducting an assay and analyzing results therefrom at separate locations, comprising:
conducting an assay on a patient sample by
contacting a uniquely encoded array of receptors with the patient sample,
wherein the uniquely encoded array of receptors is a random array comprising:
first subpopulations of encoded microparticles, wherein each first subpopulation of encoded microparticles displays a unique receptor molecule for determining if the patient sample comprises ligand capable of interacting with the unique receptor molecule;
second subpopulations of encoded microparticles, wherein each second subpopulation of encoded microparticles displays a positive or negative control receptor molecule designed to generate a signal of known magnitude to minimize variance; and
a third subpopulation of encoded microparticles, wherein said third subpopulation of encoded microparticles lack receptor molecules and are, at most, weakly encoded for correcting multiple scattering effects; and
determining if the patient sample comprises any ligands that interact with the receptors by analyzing an assay image for optical signatures that are associated with receptor-ligand interactions,
wherein the array is decoded at a location other than the location at which the assay is conducted.
2. The method of claim 1 , wherein the assay image is recorded in a first processor, wherein the array is decoded by a second processor, and wherein the first processor and the second processor communicate by way of a data network.
3. The method of claim 1 , wherein the optical signatures are one of fluorescent, luminescent, chemiluminescent, or electrochemiluminescent signatures.
4. The method of claim 1 , wherein the optical signatures are fluorescent signatures.
5. The method of claim 1 , wherein the encoded microparticles are encoded by staining with one or more fluorophore dyes.
6. The method of claim 1 , wherein the unique receptor molecule displayed by each of the first subpopulations of encoded microparticles is DNA, RNA, a peptide, a protein, an aptamer, or a small organic molecule.
7. The method of claim 1 , wherein the optical signatures from the receptors result from the association of a fluorescent entity with the ligand attached to the receptor.
8. The method of claim 1 , wherein the unique receptor molecule displayed by each of the first subpopulation of encoded microparticles relates to the presence of tumor markers, markers associated with autoimmune disorders, blood-borne viruses, therapeutic drugs, genetic mutations associated with genetic diseases, polymorphisms, or chromosomal abnormalities in the patient sample.
9. A method of analyzing a patient sample, comprising
contacting a random array of receptors with a patient sample, wherein the array comprises:
first subpopulations of encoded microparticles, wherein each of the first subpopulations of encoded microparticles displays a unique receptor molecule for determining presence of a ligand that interacts with the unique receptor molecule in the patient sample;
second subpopulations of encoded microparticles, wherein each of the second subpopulations of encoded microparticles displays a positive or a negative control receptor molecule designed to generate a signal of known magnitude to minimize variance;
a third subpopulation of encoded microparticles that lack receptor molecules and that are, at most, weakly encoded, said third subpopulation of encoded microparticles corrective for multiple scattering effects;
analyzing an assay image produced by the contacting of the random array of receptors with the patient sample;
decoding the assay image; and
analyzing the decoded assay image to determine presence of one or ligands in the patient sample,
wherein the step of decoding of the assay image and the step of contacting the random array of receptors with the patient sample are conducted at separate locations.
10. The method of claim 9 , wherein the assay image is recorded in a first processor, wherein the step of decoding is conducted by a second processor, and wherein the first processor and the second processor communicate by way of a data network.
11. The method of claim 9 , wherein the optical signatures are one of fluorescent, luminescent, chemiluminescent, or electrochemiluminescent signatures.
12. The method of claim 9 , wherein the optical signatures are fluorescent signatures.
13. The method of claim 9 , wherein the encoded microparticles are encoded by staining with one or more fluorophore dyes.
14. The method of claim 9 , wherein the unique receptor molecule displayed by each of the first subpopulations of encoded microparticles is DNA, RNA, a peptide, a protein, an aptamer, or a small organic molecule.
15. The method of claim 9 , wherein the optical signatures from the receptors result from the association of a fluorescent entity with the ligand attached to the receptor.
16. The method of claim 9 , wherein the unique receptor molecule displayed by each of the first subpopulation of encoded microparticles relates to the presence of tumor markers, markers associated with autoimmune disorders, blood-borne viruses, therapeutic drugs, genetic mutations associated with genetic diseases, polymorphisms, or chromosomal abnormalities in the patient sample.